Raven Lin
Co-Founder & CEO
Bio:
Dr. Raven Lin, PhD, MBA, is the Co-Founder and Chief Executive Officer of Pilatus Biosciences, a U.S.–Swiss biotechnology company developing next-generation immunometabolic therapies.
Before founding Pilatus, Dr. Lin served as executive of Corporate Development at I-Mab Biopharma (NASDAQ: IMAB) from 2017 to 2023, where he played a central role in shaping global strategy and driving business development. Earlier in his career, he held senior positions at Mycenax Biotech and SynCore Biotechnology, gaining extensive experience in biologics development, strategic operations, and public health initiatives. Over his career, he has led multiple high-value licensing and collaboration agreements with leading pharmaceutical companies, contributing to transactions exceeding US$3 billion.
At Pilatus, Dr. Lin is spearheading the development of PLT012, a first-in-class humanized anti-CD36 antibody with dual immunometabolic mechanisms. Since 2023, under his leadership, the company has secured FDA Orphan Drug Designation, established a clinical supply partnership with Roche, and is advancing toward IND submission and first-in-human trials within the next six months.